Type-1 ribosome-inactivating protein
AssigneeTanox Pharma B.V.
InventorsFiorenzo Stirpe, Andrea Bolognesi
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel ribosome-binding protein derived from Bougainvillea spectabilis having a molecular weight of about 26,000 daltons by polyacrylamide gel electrophoresis under reducing and non-reducing conditions, a pI of about 9.0, and a specified amino-terminal amino acid sequence. The invention further relates to a conjugate of the protein with a targeting ligand, such as an antibody, to form an immunotoxin. The protein and the conjugate are useful in therapy, for example, in the control of tumour cells or viruses.
Claims8
An isolated B. spectabilis polynucleotide comprising SEQ ID NO:
- 8, wherein the polynucleotide encodes a polypeptide that has ribosome inactivation protein activity.
A recombinant vector comprising the polynucleotide according to claim l.
An isolated B. spectabilis polynucleotide encoding a polypeptide comprising SEQ ID NO:
- 9, wherein the encoded polypeptide has ribosome inactivating protein activity.
Dependencies are inferred from the claim text.